Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study

Anita M Leys,1,2 Eva Ramboer,3 Mérédis Favreau,3 Kris Denhaerynck,4,5 Karen MacDonald,4 Ivo Abraham,4,6– 8 Heidi Brié3 1Department of Ophthalmology, Universitair Ziekenhuis Gasthuisberg, KULeuven, Leuven, Belgium; 2Oogartsen, Alken, Belgium; 3Novartis Pharma, Vilvoorde, Belgium; 4Matrix45, Tucson, AZ, USA; 5Department of Public Health, University of Basel, Basel, Switzerland; 6Center for Health Outcomes and Pharmacoeconomic Research, University of Arizona, Tucson, AZ, USA; 7Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA; 8Department of... Mehr ...

Verfasser: Leys AM
Ramboer E
Favreau M
Denhaerynck K
MacDonald K
Abraham I
Brié H
Dokumenttyp: Artikel
Erscheinungsdatum: 2020
Reihe/Periodikum: Clinical Ophthalmology, Vol Volume 14, Pp 1473-1481 (2020)
Verlag/Hrsg.: Dove Medical Press
Schlagwörter: ranibizumab / effectiveness / safety / treatment patterns / neovascular age-related macular degeneration / belgium / Ophthalmology / RE1-994
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26500935
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doaj.org/article/35f925692fde4e26a8d9ad49bdc346d0